Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)

Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)

The global RNAi therapeutics market is expected to record a value of US$1.26 billion in 2028, progressing at a CAGR of 10.02%, over the period 2024-2028. Factors such as rising utilization in oncology pharmaceuticals, accelerating growth rates of infectious diseases, enlarging geriatric population, increasing prevalence of neurodegenerative disorders and progress in collaborations and associated deals in RNAi therapeutics. However, the market growth would be challenged by complexity associated with the drug delivery of RNAi therapeutics, high development cost of RNA interference-based therapeutics and stringent regulatory requirements. A few notable trends include growing popularity of personalized medicine, surging preference RNAi therapeutics as an alternative for HTS & keloids treatment and escalating applications in molecular diagnostics.

The global market has been segmented on the basis of molecule type, application and end-user. On the basis of molecule type, the global market can be bifurcated into small interfering RNAs (siRNAs) and microRNAs (miRNAs). According to applications, the market can be divided into oncology, respiratory disorders, neurological disorders, liver disorders, autoimmune disorders and other disorders. Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.

The fastest growing regional market is North America owing to increasing prevalence of chronic conditions, rising investments for development of RNAi therapeutics along with growing number of research activities for RNA-based therapeutics in the region. Further, the COVID-19 pandemic has positively impacted the market due to the growing relevance of RNA-based investigations as well as increasing funding for R&D activities.

Scope of the report:

• The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.
• The major regional and country markets (North America, Europe, Asia Pacific and RoW) have been analyzed.
• The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players (Sanofi S.A., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Benitec Biopharma Ltd., and Sirnaomics, Ltd.) are also presented in detail.

Key Target Audience:

• RNAi Therapeutics Service/Equipment Providers and Distributors
• Pharmaceutical, Biopharmaceutical & Biotechnological Companies
• Research and Development (R&D) Organizations
• End Users
• Government Bodies & Regulating Authorities